Author: admin

  • Corticosteroids may reduce effectiveness of immunotherapy in lung cancer

    Corticosteroids may reduce effectiveness of immunotherapy in lung cancer

    Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to new research by Keck Medicine of USC. 

    The study, published today in Cancer Research Communications, showed that high doses of steroids, when given before and/or during a specific type of immunotherapy, caused patients’ tumors to shrink less than those of patients not on steroids. Those patients also did not live as long. 

    Steroids were the biggest predictor of why certain immunotherapies may not be effective, even when considering multiple other factors such as stage and progression of the disease.”


    Fumito Ito, MD, PhD, Keck Medicine oncologist and immunologist, lead author of the research

    Additionally, researchers believe they have found the mechanism behind why steroids and some immunotherapies may not mix. 

    “Our findings reveal that steroids stop the body’s natural cancer-fighting cells, T-cells, from maturing. This makes them unable to attack the cancer as vigorously as they usually would, leading to worse outcomes for patients,” said Ito, who is also a member and co-leader of the translational and clinical sciences research program at USC Norris Comprehensive Cancer Center. “While other research has indicated steroids may negatively impact immunotherapy’s efficacy, we are one of the first to pinpoint a probable cause and effect.” 

    Ito and his colleagues also discovered that steroids blocked circulating biomarkers in the body – bits of cells in the bloodstream that signal when cancer is progressing so oncologists can adjust the patient’s treatment. 

    “Without the presence of circulating biomarkers to inform our decisions, oncologists cannot treat the cancer as effectively and patients may miss out on the best treatment for their cancer,” said Ito. 

    Two competing medications 

    The study examined the effect of steroids on a type of immunotherapy known as immune checkpoint inhibitors (ICIs). ICIs help the body’s immune system fight cancer by blocking proteins that prevent T-cells from attacking cancer cells. ICIs are often used to treat non-small cell lung cancer, the most common form of lung cancer. 

    Steroids are often prescribed to alleviate symptoms of the cancer or treatments given for a variety of reasons, such as fatigue and vomiting, or more serious side effects like brain swelling and lung inflammation. Steroids suppress the immune system, which reduces the inflammation that can cause these conditions. 

    How the studies were conducted 

    Ito and fellow researchers retrospectively studied the medical records of 277 patients with Stage II-IV non-small cell lung cancer who were treated with ICIs alone or in combination with other therapies. They compared outcomes (tumor shrinkage and survival rate) between patients prescribed steroids and those who were not at three centers, including USC Norris Comprehensive Cancer Center. 

    They analyzed up to eight years of data to determine that steroids were the sole factor impeding the effectiveness of the immunotherapy. 

    They also determined that the T-cells of significant numbers of patients on steroids were not fully matured and launched a preclinical study using mice to observe the effects of steroids on ICI therapy in real time. This mouse model study led to the discovery that steroids given before/during immunotherapy inhibit T-cells from fully maturing. 

    The future of steroids 

    While the Keck Medicine research indicates steroids can interfere with ICIs, Ito acknowledges that for some patients, steroids may be necessary to manage their cancer-related symptoms. 

    “We know that steroids will continue to play an important role in lung cancer care, but it is important to understand their potential limitations,” said Ito. “Each patient should talk to their oncologist to make sure they have the best possible care plan tailored to their specific needs.” 

    He hopes this research will lead to more studies examining the effect of steroids on immunotherapy so oncologists can make fully informed decisions that will best benefit their patients. 

    Other study authors include Keck Medicine medical oncologists Jorge Nieva, MD and Robert Hsu, MD. 

    The study was supported with grants from the National Cancer Institute, P30CA016056 (RPCCC), P30CA014089 (USC), K08CA197966, R01CA255240, R01CA272827 (F. Ito), R01CA188900, R01CA267690 (B.H. Segal) as well as the Department of Defense Lung Cancer Research Program and the Uehara Memorial Foundation. 

    Source:

    University of Southern California – Health Sciences

    Journal reference:

    Polyakov, L., et al. (2025). Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients. Cancer Research Communications. doi.org/10.1158/2767-9764.crc-25-0051.

    Continue Reading

  • Is this the ‘best version’ of Spain midfielder Alexia Putellas?

    Is this the ‘best version’ of Spain midfielder Alexia Putellas?

    Alexia Putellas: I am the best version of myself

    After missing out on this competition three years ago, Alexia Putellas is well and truly making up for lost time in Switzerland.

    She arrived at EURO 2025 on the back of her best individual campaign since an ACL injury that kept her sidelined for a lengthy spell.

    In fact, her 16 goals and 11 assist return in 24/25 is the second-best outing of her career in the Primera Division overall.

    Evidently, this is a player who is no stranger to stepping up in the big moments.

    In Spain’s opening two games of Group B she has done exactly that, registering three goals and two assists in victories over Portugal and Belgium.

    The second of these outings came with some difficulty, the tournament favourites pegged back twice by their Belgian counterparts before eventually cruising to all three points.

    Alexia’s performances have gone far beyond being clinical in front of goal, grabbing each game by the scruff of its neck and leading the charge for a title she is eager to win.

    It therefore begs the question: Is this the best version of two-time Ballon d’Or winner Putellas?

    She certainly thinks so.

    “For me, without a doubt, I am the best Alexia,” she said at Spain’s pre-Euros camp.

    “I know myself much better, I know what my qualities are, I know what those are in my work.

    “All the suffering [injuries] at the end make you evolve as a person and as an athlete; I know how to manager bad moments better and I know to savour the good moments too.”

    Putellas is playing with the confidence and fluidity that propelled her to stardom prior to that knee injury, with Spain the biggest beneficiaries.

    A potential third Ballon d’Or could be on the horizon for the midfielder, who played talk of it down in the media.

    For right now, her focus remains on fighting for the collective cause: EURO 2025.

    Continue Reading

  • Iran’s president says open to dialogue with US after Israel war | Israel-Iran conflict News

    Iran’s president says open to dialogue with US after Israel war | Israel-Iran conflict News

    Israel attacked Iran just days before Tehran and Washington were to meet for a new round of nuclear talks.

    Iranian President Masoud Pezeshkian has said he believes Tehran can resolve its differences with the United States through dialogue, but trust would be an issue after US and Israeli attacks on his country.

    “I am of the belief that we could very much easily resolve our differences and conflicts with the United States through dialogue and talks,” Pezeshkian told US right-wing podcaster Tucker Carlson in an interview conducted on Saturday and released on Monday.

    His remarks came less than a month after Israel launched its unprecedented June 13 bombing campaign against Iran, killing top military commanders and nuclear scientists.

    The Israeli attacks took place two days before Tehran and Washington were set to meet for a new round of nuclear talks, stalling negotiations that were aimed at reaching a deal over Iran’s atomic programme.

    A week later, in separate attacks on June 21, the US also bombed three Iranian nuclear facilities at Fordow, Natanz and Isfahan.

    Iranian state media said on Monday that the death toll from the 12-day war had risen to at least 1,060.

    Pezeshkian blamed Israel, Iran’s archenemy, for the collapse of talks with the US.

    “How are we going to trust the United States again?” he asked.

    “How can we know for sure that in the middle of the talks, the Israeli regime will not be given the permission again to attack us?”

    Iran’s president also accused Israel of attempting to assassinate him during the June attacks.

    “They did try, yes. They acted accordingly, but they failed,” Pezeshkian told Carlson in response to a question on whether he believed Israel had tried to kill him.

    “It was not the United States that was behind the attempt on my life. It was Israel. I was in a meeting … they tried to bombard the area in which we were holding that meeting,” he said, according to a translation of his remarks from Persian into English.

    On June 16, Israeli Prime Minister Benjamin Netanyahu also did not rule out plans to assassinate Iran’s Supreme Leader Ayatollah Ali Khamenei, saying it would “end the conflict” after reports emerged at the time that US President Donald Trump had vetoed the move.

    While a ceasefire between Iran and Israel has been in place since June 24, during the interview with Carlson, Pezeshkian accused Netanyahu of pursuing his “own agenda” of “forever wars” in the Middle East and urged Trump not to be drawn into war with Iran by the Israeli leader.

    Netanyahu is visiting Washington on Monday for talks at the White House.

    “The United States’ president, Mr. Trump, he is capable enough to guide the region towards peace and a brighter future and put Israel in its place. Or get into a pit, an endless pit, or a swamp,” Pezeshkian said.

    “So it is up to the United States president to choose which path.”

    Trump said he expected to discuss Iran and its nuclear ambitions with Netanyahu, praising the US strikes on Iranian nuclear sites as a tremendous success.

    On Friday, he told reporters that he believed Tehran’s nuclear programme had been set back permanently, although Iran could restart efforts elsewhere.

    Continue Reading

  • An HPLC 2025 Interview with Paul Ferguson

    An HPLC 2025 Interview with Paul Ferguson

    Key Points

    • Ferguson highlights the move toward replacing traditional acids like trifluoroacetic acid (TFA) and difluoroacetic acid (DFA) with methanesulfonic acid (MSA) in peptide analysis. This change reduces environmental impact due to lower toxicity and better biodegradability. However, it comes with trade-offs, including potential impacts on chromatographic performance and sensitivity, requiring careful method optimization.

    • A key strategy for sustainability is reducing mobile phase volumes, which directly reduces solvent waste and resource consumption. This is especially relevant for high-throughput labs. However, Ferguson notes practical limitations, such as ensuring method robustness and reproducibility at lower flow rates, which can affect data quality if not well-controlled.

    • Ferguson emphasizes the environmental benefits of on/off LC–MS mechanisms compared to traditional continuous-flow systems. On/off systems reduce solvent and energy usage when not actively analyzing samples. Nonetheless, they require method redesign and equipment adaptation, especially in older systems not originally built for intermittent use.

    As the pharmaceutical industry moves toward more sustainable and responsible practices, the spotlight is turning to analytical techniques—and how they must evolve to meet both scientific and environmental demands. In this special HPLC 2025 interview with LCGC International, we sit down with Paul Ferguson, a leading voice in sustainability in the pharmaceutical sector, to explore the intersection of green chemistry and emerging therapeutics.

    Ferguson shares insights on how method design is adapting to support sustainability in the development of new modality therapeutics. We discuss the practicalities and trade-offs of greener alternatives—such as replacing trifluoroacetic acid (TFA) with methanesulfonic acid.

    From mobile phase volume reduction to the environmental implications of liquid chromatography–mass spectrometry (LC–MS) flow strategies, this discussion offers a forward-looking perspective on what it means to build analytical methods that are not only effective but also sustainable.

    Ferguson addressed the following questions:

    • As sustainability becomes a key consideration in pharmaceutical development, how is chromatographic method design evolving to support greener practices, particularly for new modality therapeutics such as peptides and oligonucleotides?

    • What are the primary sustainability benefits and trade-offs of using MSA (methanesulfonic acid) as a replacement for TFA/DFA in peptide analysis?

    • How can reducing mobile phase volumes serve as a practical strategy for reducing the environmental impact of chromatographic methods, and what limitations might be encountered?

    • What impact does the on/off mechanism have on sustainability, particularly in non-optimized LC–MS systems, and how does it compare to traditional continuous-flow approaches?

    • Do you have general advice on how separation science can become more sustainable?

    Paul Ferguson was appointed professor by special appointment at the Faculty of Science of the University of Amsterdam, Netherlands, in March 2025. His chair, “Separation of Biomacromolecules, with an Emphasis on Sustainable Analytical Science,” is part of the Van ‘t Hoff Institute for Molecular Sciences (HIMS) and endowed by the Bèta Plus foundation. He is also an active member of The Chromatographic Society (ChromSoc) and LCGC international’s editorial advisory board (EAB).

    Continue Reading

  • Samsung SmartThings Rolls Out AI-Powered Automation, Expanded iOS Capabilities and Streamlined Onboarding

    Samsung SmartThings Rolls Out AI-Powered Automation, Expanded iOS Capabilities and Streamlined Onboarding

    Samsung has released a major update to its SmartThings platform, introducing a range of features designed to simplify home automation, enhance compatibility with Apple devices, and streamline device setup. The update continues SmartThings’ push toward a more intuitive, cross-platform connected living experience.

    AI-Powered Routine Creation Makes Automation Easier

    At the center of the update is the new Routine Creation Assistant, a feature powered by large language models that lets users build automations using simple phrases. For example, typing “Turn off all the lights when I leave the house” automatically creates a routine that matches the request. This tool is now available for Samsung account holders in the U.S. and Korea on both Android and iOS.

    Samsung says the assistant is designed to make smart home automation more accessible for beginners while also offering a faster and more efficient setup process for experienced users.

    More Granular Control with Delayed Actions and Confirmations

    SmartThings now supports layered routines through a new Delay Actions capability. Users can schedule multiple steps within a single routine. A “Good Morning” routine, for instance, can turn on bedroom lights at 7:00 a.m., start the coffee maker at 7:15, and open the curtains while playing music at 7:30.

    The update also introduces a Confirm to Run Actions feature. Before executing a routine, users can choose to receive a prompt asking whether to proceed. This helps avoid unintentional triggers, especially in households with multiple members.

    Calm Onboarding Now Available in 58 Countries

    SmartThings has expanded its Calm Onboarding program, which streamlines the setup process for Samsung products purchased through Samsung.com or Samsung retail stores. When users buy an eligible product, SmartThings can automatically detect, register, and connect it to the app. With the latest update, Calm Onboarding is available in 58 countries, up from 14, and now includes Galaxy Watches, Buds, and select partner devices in Korea and the UK.

    Enhanced Location Sharing with SmartThings Find

    SmartThings Find, Samsung’s location tracking service with more than 67 million users, has also been upgraded. Galaxy users can now share the location of SmartTags via a link. Recipients, including iOS users, can use the link to track tagged items like bags or pet collars after logging in with a Samsung account.

    This enhancement improves coordination in multi-device households and makes it easier to track shared items regardless of platform.

    New Features for iOS Users

    For iOS users, Samsung has introduced a SmartThings widget for Apple Watch. The widget allows users to control smart home devices, manage routines, and switch locations directly from their watch. The iOS app also now includes a Dark Mode option for more comfortable viewing in low-light conditions and improved battery efficiency.

    Explore SmartThings with Virtual Home

    SmartThings has launched a new Virtual Home tool that gives users a simulated smart home experience without needing to connect real devices. It allows exploration of features like routine creation, SmartThings Energy, and pet tracking. This experience helps users understand the platform’s capabilities before committing to physical hardware.

    Continued Focus on Personalized Connected Living

    “This SmartThings update will help anyone easily create a smart home that fits their lifestyle,” said Mark Benson, Head of SmartThings US. “SmartThings will continue to innovate so users can spend less time managing devices and more meaningful time with their families.”

    Continue Reading

  • New investigation reveals potentially fatal side effects of popular weight-loss drugs

    New investigation reveals potentially fatal side effects of popular weight-loss drugs

    Image credits: Getty Images

    Every coin has two sides and so does every miracle. While it gives a person an advantage, it also gives them a disadvantage. Popular weight-loss drugs like Ozempic have been revolutionary in weight loss with a plethora of celebrities jumping on the bandwagon. However, their side-effects including tooth decay, droopy face, saggy butt and hair loss have not been hidden from the eyes of all.Now, a UK regulator is shedding light on much more serious and potentially fatal side effects of these drugs. The UK’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the official system for collecting and monitoring reports of suspected side effects or reactions to drugs and devices, has recently received over 400 reports of serious pancreas trouble from users of GLP-1.

    Over 400 reports of serious pancreas trouble from users of GLP-1

    Image credits: Getty Images

    Acute pancreatitis is a sudden and extremely painful inflammation of the pancreas that causes people severe abdominal pain, nausea and fever. In the UK, there have been at least 10 deaths linked to this condition among users of GLP-1. Among the users of Mounjaro, there have been 181 reported cases of acute or chronic pancreatitis with 5 deaths.While the pamphlets on these famous drugs note that pancreatitis is an uncommon reaction that only affects one in 100 users, the condition is deemed serious enough to require an investigation.

    Higher risk of developing pancreatitis while taking GLP-1 drugs?

    Image credits: Getty Images

    “Sometimes genes can influence the side‑effects an individual experiences when taking a medicine,” the MHRA told The Guardian. Thus along with Genomics England, MHRA is launching a new study to see if people’s genes put them at a higher risk of developing pancreatitis while taking GLP-1 drugs. Those who have pancreatitis while using the jabs will be asked to provide a saliva sample and have their genes tested.Novo Nordisk, which produces Ozempic and Wegovy, advised people to take the medications only for their approved indications and under the strict supervision of a healthcare professional. “We continuously collect safety data on our marketed GLP-1 medicines and work closely with the authorities to ensure patient safety. The benefit-risk profile of our GLP-1 medicines remains positive, and we welcome any new research that will improve our understanding of treatments for people living with chronic diseases,” they told the outlet.


    Continue Reading

  • How to reach the F3 Crater in Death Stranding 2? | Esports News

    How to reach the F3 Crater in Death Stranding 2? | Esports News

    The F3 Crater isn’t just a hauntingly beautiful location in Death Stranding 2; it’s also tied to one of the game’s most elusive trophies. But don’t worry, you won’t have to wander blindly through tar lakes and BT zones to find it. This quick guide breaks down exactly when and how to reach the F3 Crater.

    Step 1: Progress the Story Until Order 29

    Before you even think about setting foot near the crater, make sure you’ve completed Order 29. This mission links the Mechanic to the Chiral Network and unlocks a key piece of equipment: the Coffin Board.No, it’s not just a flashy name—it’s your one and only reliable ride across the deadly tar terrain surrounding the crater.

    Making An S Tier Delivery Using The New Coffin Board In Death Stranding 2

    Step 2:Unlock and Fabricate the Coffin Board

    Once the board is available, head to a fabrication terminal at a major facility like Heartman’s Lab or DHV Magellan.You’ll need:

    • 260 Metals
    • 200 Ceramics
    • 30 Chemicals

    Once built, keep in mind that the Coffin Board only works within the Chiral Network. So make sure the surrounding area is fully connected—especially Heartman’s Lab.

    Step 3: Head North from Heartman’s Lab

    From Heartman’s Lab, travel north toward the tar-filled basin. The F3 Crater sits like a black eye in the center of it all. Use the Coffin Board to float over the tar lake. Traditional vehicles will sink, so don’t even try.

    Step 4: Watch for the BT Alert

    As you near the crater, your Odradek will start spinning, and you’ll be in the BT territory.You can:

    • Speed through to avoid encounters
    • Equip anti-BT weapons if you want to fight
    • Sneak carefully if you’re low on supplies

    Your call, but be cautious. BTs in this area are aggressive.

    Death Stranding 2: The Scars Left by the Giants Trophy Guide – How to Reach the BT Nexus (F3 Crater)

    Step 5: Reach the Island at the Center (Optional)

    Once you cross the tar and hit the crater, you’ll unlock the “The Scars Left by the Giants” trophy.Want to explore further? There’s a mysterious island in the center of the crater. You can glide toward it with the board—but be warned: it’s crawling with BTs. Only go if you’re geared up.

    Bonus: Unlock Fast Access Later

    If you’re not in a rush, you can wait until you’ve unlocked the Adventurer and raised their connection to Level 5. This opens up Sub Order 121, which teleports you directly to the crater, trophy included.Don’t go in empty-handed. Pack weapons, blood bags, and spare materials. The F3 Crater is breathtaking, but it’s not a tourist spot. Be ready for a fight—or a fast getaway.


    Continue Reading

  • John Slattery, Jessica Henwick Among 9 Cast in Netflix Show ‘Vladimir’

    John Slattery, Jessica Henwick Among 9 Cast in Netflix Show ‘Vladimir’

    Netflix‘s limited series adaptation of the Julia May Jonas novel “Vladimir” is rounding out its main cast.

    Nine new cast members have joined the series alongside previously announced leads Rachel Weisz and Leo Woodall. Variety has learned that John Slattery (“Mad Men,” “Spotlight,” “Nuremberg”), Jessica Henwick (“Glass Onion: A Knives Out Mystery,” “Silo”), and Ellen Robertson (“Mickey 17,” “Black Mirror,” “Too Much”) have been cast as series regulars in the roles of John, Cynthia, and Sid respectively.

    The new recurring cast members are: Kayli Carter (“The Marvelous Mrs. Maisel,” “Mrs. America,” “Private Life”) as Lila, Miriam Silverman (“Your Friends and Neighbors,” “The Sign in Sidney Brustein’s Window”) as Florence, Mallori Johnson (“Is God Is,” “Steal Away”) as Edwina, Matt Walsh (“Veep,” “Ghosts,” “Novocaine”) as David, Tattiawna Jones (“Murderbot,” “Station Eleven”) as Alexis, and Louise Lambert (“Chucky,” “Doc,” “Ginny & Georgia”) as Dawn.

    In addition, the Oscar-nominated and Emmy-winning team of Shari Springer Berman and Robert Pulcini (“Fleishman Is in Trouble,” “American Splendor”) are set to direct three of the show’s eight episodes, including the pilot. They will also be executive producers on the series.

    The official logline for the show states, “As a woman’s (Weisz) life unravels, she becomes obsessed with her captivating new colleague (Woodall). Full of sexy secrets, dark humor and complex characters, ‘Vladimir’ is about what happens when a woman goes hell-bent to turn her fantasies into reality.”

    Jonas is adapting her book for the screen and also serves as executive producer on the series. Weisz will executive produce in addition to starring. Sharon Horgan, Stacy Greenberg, and Kira Carstensen executive produce via Merman along Jason Winer & Jon Radler of Small Dog Picture Company, as well as Springer Berman and Pulcini. 20th Television is the studio.

    (Pictured from top left, left to right: John Slattery, Jessica Henwick, Ellen Robertson, Kayli Carter, Matt Walsh, Tattiawna Jones, Mallori Johnson, Louise Lambert, Miriam Silverman)

    Continue Reading

  • Citizen Astronomers Help Confirm New Temperate Jupiter

    Citizen Astronomers Help Confirm New Temperate Jupiter

    Other citizen science groups contributed as well, including the TESS Follow-up Observing Program Sub Group 1 (TFOP SG1) and the TESS Single Transit Planet Candidate (TSTPC) Working Group, making this a truly communal endeavor. Thanks to everyone’s combined efforts, astronomers were able to finally confirm the existence of TOI-4465b.

    “The discovery and confirmation of TOI-4465 b not only expands our knowledge of planets in distant star systems but also shows how passionate astronomy enthusiasts can play a direct role in frontier scientific research,” said Dr. Zara Essack, Postdoctoral Fellow at the University of New Mexico and lead author of the study. “It’s a powerful example of citizen science, teamwork, and the importance of global collaboration in astronomy.”

    This isn’t the first planet confirmed with help from the SETI & Unistellar Network, which is particularly well-suited for such discoveries.

    “Now, people equipped with a digital smart telescope can observe and confirm exoplanets from their backyard, helping NASA map nearby planetary systems discovered by the TESS mission,” said Dr. Franck Marchis, Senior Astronomer at the SETI Institute and Chief Scientific Officer at Unistellar. “The likelihood of TESS observing another transit of a planet like TOI-4465 b, which happens only every 102 days, is low. So the SETI & Unistellar network is essential for these discoveries.”

    TOI-4465 b represents an important piece of the planetary puzzle, helping bridge the gap between hot Jupiters that orbit close to their stars and our own Solar System’s cold gas giants. This new world is a “temperate” Jupiter: it shares some orbital properties with warm Jupiters, but its modest orbital eccentricity keeps its temperature relatively mild. TOI-4465 b is the most massive long-period giant known to transit a sub-solar metallicity star and has the largest radius of any known planet with an orbital period exceeding 100 days. As a result, it provides a unique test case for studying gas giants and helps fill gaps in our planetary knowledge.

    “It’s really astounding what science can achieve when we work together,” said Dr. Lauren Sgro, Postdoctoral Fellow at the SETI Institute and co-author of the study. “I’m excited to see how future observations of this planet inform our understanding of gas giant formation, and knowing that citizen scientists are part of this process is truly inspiring.”

    TOI-4465 b is also well-suited for follow-up studies of its atmosphere with instruments such as the James Webb Space Telescope, so this is only the beginning of its story. Perhaps the next chapter belongs to another new planet, waiting to be explored by professional and citizen astronomers alike.

    Continue Reading

  • MIT chemists boost the efficiency of a key enzyme in photosynthesis | MIT News

    MIT chemists boost the efficiency of a key enzyme in photosynthesis | MIT News

    During photosynthesis, an enzyme called rubisco catalyzes a key reaction — the incorporation of carbon dioxide into organic compounds to create sugars. However, rubisco, which is believed to be the most abundant enzyme on Earth, is very inefficient compared to the other enzymes involved in photosynthesis.

    MIT chemists have now shown that they can greatly enhance a version of rubisco found in bacteria from a low-oxygen environment. Using a process known as directed evolution, they identified mutations that could boost rubisco’s catalytic efficiency by up to 25 percent.

    The researchers now plan to apply their technique to forms of rubisco that could be used in plants to help boost their rates of photosynthesis, which could potentially improve crop yields.

    “This is, I think, a compelling demonstration of successful improvement of a rubisco’s enzymatic properties, holding out a lot of hope for engineering other forms of rubisco,” says Matthew Shoulders, the Class of 1942 Professor of Chemistry at MIT.

    Shoulders and Robert Wilson, a research scientist in the Department of Chemistry, are the senior authors of the new study, which appears this week in the Proceedings of the National Academy of Sciences. MIT graduate student Julie McDonald is the paper’s lead author.

    Evolution of efficiency

    When plants or photosynthetic bacteria absorb energy from the sun, they first convert it into energy-storing molecules such as ATP. In the next phase of photosynthesis, cells use that energy to transform a molecule known as ribulose bisphosphate into glucose, which requires several additional reactions. Rubisco catalyzes the first of those reactions, known as carboxylation. During that reaction, carbon from CO2 is added to ribulose bisphosphate.

    Compared to the other enzymes involved in photosynthesis, rubisco is very slow, catalyzing only one to 10 reactions per second. Additionally, rubisco can also interact with oxygen, leading to a competing reaction that incorporates oxygen instead of carbon — a process that wastes some of the energy absorbed from sunlight.

    “For protein engineers, that’s a really attractive set of problems because those traits seem like things that you could hopefully make better by making changes to the enzyme’s amino acid sequence,” McDonald says.

    Previous research has led to improvement in rubisco’s stability and solubility, which resulted in small gains in enzyme efficiency. Most of those studies used directed evolution — a technique in which a naturally occurring protein is randomly mutated and then screened for the emergence of new, desirable features.

    This process is usually done using error-prone PCR, a technique that first generates mutations in vitro (outside of the cell), typically introducing only one or two mutations in the target gene. In past studies on rubisco, this library of mutations was then introduced into bacteria that grow at a rate relative to rubisco activity. Limitations in error-prone PCR and in the efficiency of introducing new genes restrict the total number of mutations that can be generated and screened using this approach. Manual mutagenesis and selection steps also add more time to the process over multiple rounds of evolution.

    The MIT team instead used a newer mutagenesis technique that the Shoulders Lab previously developed, called MutaT7. This technique allows the researchers to perform both mutagenesis and screening in living cells, which dramatically speeds up the process. Their technique also enables them to mutate the target gene at a higher rate.

    “Our continuous directed evolution technique allows you to look at a lot more mutations in the enzyme than has been done in the past,” McDonald says.

    Better rubisco

    For this study, the researchers began with a version of rubisco, isolated from a family of semi-anaerobic bacteria known as Gallionellaceae, that is one of the fastest rubisco found in nature. During the directed evolution experiments, which were conducted in E. coli, the researchers kept the microbes in an environment with atmospheric levels of oxygen, creating evolutionary pressure to adapt to oxygen.

    After six rounds of directed evolution, the researchers identified three different mutations that improved the rubisco’s resistance to oxygen. Each of these mutations are located near the enzyme’s active site (where it performs carboxylation or oxygenation). The researchers believe that these mutations improve the enzyme’s ability to preferentially interact with carbon dioxide over oxygen, which leads to an overall increase in carboxylation efficiency.

    “The underlying question here is: Can you alter and improve the kinetic properties of rubisco to operate better in environments where you want it to operate better?” Shoulders says. “What changed through the directed evolution process was that rubisco began to like to react with oxygen less. That allows this rubisco to function well in an oxygen-rich environment, where normally it would constantly get distracted and react with oxygen, which you don’t want it to do.”

    In ongoing work, the researchers are applying this approach to other forms of rubisco, including rubisco from plants. Plants are believed to lose about 30 percent of the energy from the sunlight they absorb through a process called photorespiration, which occurs when rubisco acts on oxygen instead of carbon dioxide.

    “This really opens the door to a lot of exciting new research, and it’s a step beyond the types of engineering that have dominated rubisco engineering in the past,” Wilson says. “There are definite benefits to agricultural productivity that could be leveraged through a better rubisco.”

    The research was funded, in part, by the National Science Foundation, the National Institutes of Health, an Abdul Latif Jameel Water and Food Systems Lab Grand Challenge grant, and a Martin Family Society Fellowship for Sustainability.

    Continue Reading